Denali Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Denali Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,900	Closed	-$200K	–	483
2023 Q2	$200K	Buy	+14,900	New	+$214K	0.07%	214

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Denali Advisors's CPRX Position: Q3 2023 in Review

Denali Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 14,900 shares — an estimated $200K sold.

Denali Advisors first reported a position in CPRX in Q2 2023 and held it in 1 quarter. The position peaked at $200K in Q2 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

Denali Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
Denali Advisors sold 14,900 Catalyst Pharmaceutical shares in Q3 2023, an estimated $200K.
Denali Advisors first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 1 quarter.
Denali Advisors's Catalyst Pharmaceutical position peaked at $200K in Q2 2023.
255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.